ライフサイエンスコーパス: lateral sclerosis

1 iants in Parkinson's disease and amyotrophic lateral sclerosis".

2 dismutase 1 (linked to familial amyotrophic lateral sclerosis).

3 disease, Huntington disease, and amyotrophic lateral sclerosis.

4 to motor neuron degeneration in amyotrophic lateral sclerosis.

5 of motoneuron disorders such as amyotrophic lateral sclerosis.

6 D1(G93A) mice, a mouse model for amyotrophic lateral sclerosis.

7 o forms aggregates implicated in amyotrophic lateral sclerosis.

8 disease, muscular dystrophy, and amyotrophic lateral sclerosis.

9 in cellular and mouse models of amyotrophic lateral sclerosis.

10 es such as Parkinson disease and amyotrophic lateral sclerosis.

11 ety of human diseases, including amyotrophic lateral sclerosis.

12 iated with sporadic and familial amyotrophic lateral sclerosis.

13 nd the later stages can resemble amyotrophic lateral sclerosis.

14 outcome of the motor function in amyotrophic lateral sclerosis.

15 neurodegenerative diseases like amyotrophic lateral sclerosis.

16 but not Huntington's disease or amyotrophic lateral sclerosis.

17 y open angle glaucoma (POAG) and amyotrophic lateral sclerosis.

18 implication in diseases including cancer and lateral sclerosis.

19 sponse pathway is compromised in amyotrophic lateral sclerosis.

20 expanded in the C9orf72 form of amyotrophic lateral sclerosis.

21 rosis and patients with sporadic amyotrophic lateral sclerosis.

22 of autosomal recessive juvenile amyotrophic lateral sclerosis.

23 o frontotemporal dementia and/or amyotrophic lateral sclerosis.

24 n (MSPd) that is associated with amyotrophic lateral sclerosis.

25 FUS and pathology of FUS-related amyotrophic lateral sclerosis.

26 signaling function implicated in amyotrophic lateral sclerosis.

27 e properties approved for use in amyotrophic lateral sclerosis.

28 cic dysplasia, Mohr-syndrome and amyotrophic lateral sclerosis.

29 o amyloid-like fibrils linked to amyotrophic lateral sclerosis.

30 disease progression of familial amyotrophic lateral sclerosis.

31 ed to various diseases including amyotrophic lateral sclerosis.

32 tent with an oligogenic basis of amyotrophic lateral sclerosis.

33 cipients had cancer, 79 (8%) had amyotrophic lateral sclerosis, 44 (4.5%) had lung disease, 26 (2.6%)

34 in motor neuron degeneration of amyotrophic lateral sclerosis, abnormalities of RNA/RNA-binding prot

35 ouble fluorescence, including in amyotrophic lateral sclerosis-affected cranial nerve motor nuclei bu

36 ggregation of which is linked to amyotrophic lateral sclerosis (ALS) - a fatal neurodegenerative dise

37 N1) are mutated in patients with amyotrophic lateral sclerosis (ALS) [5, 6].

38 glected symptom in patients with amyotrophic lateral sclerosis (ALS) although it is reported by most

39 reviously found in patients with amyotrophic lateral sclerosis (ALS) and developmental delay, intelle

40 date the genetic architecture of amyotrophic lateral sclerosis (ALS) and find associated loci, we ass

41 (STRs), such as those that cause amyotrophic lateral sclerosis (ALS) and fragile X syndrome, is chall

42 f72 are the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration

43 two neurodegenerative syndromes, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

44 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

45 xity of the genetic landscape in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

46 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

47 RF72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

48 RF72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

49 ntribute to neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

50 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

51 ing behaviours and metabolism in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

52 on TDP-43, an RBP implicated in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

53 RNA-binding protein involved in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

54 ous tissue of most cases of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

55 the most frequent known cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

56 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

57 Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD

58 particularly high prevalence in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD

59 the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, tho

60 en linked to the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

61 degenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

62 involved in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degener

63 s a hallmark of certain forms of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degener

64 Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degener

65 involved in the pathogenesis of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Dementi

66 he neuroinflammatory reaction in amyotrophic lateral sclerosis (ALS) and is toxic for motor neurons.

67 chronic low back pain (cLBP) or amyotrophic lateral sclerosis (ALS) and matching healthy controls re

68 The study of amyotrophic lateral sclerosis (ALS) and potential interventions woul

69 cally and functionally linked to amyotrophic lateral sclerosis (ALS) and regulates transcription, spl

70 the survival of motor neurons in amyotrophic lateral sclerosis (ALS) and that the combined delivery o

71 tion of corticospinal neurons in amyotrophic lateral sclerosis (ALS) and to neocortical hyperexcitabi

72 The etiological underpinnings of amyotrophic lateral sclerosis (ALS) are complex and incompletely und

73 s isolated from individuals with amyotrophic lateral sclerosis (ALS) are toxic to motor neurons (MNs)

74 ong-term epidemiologic trends of amyotrophic lateral sclerosis (ALS) based on a prospective register.

75 in the C9orf72 form of heritable amyotrophic lateral sclerosis (ALS) binds to the central channel of

76 A proportion of Amyotrophic lateral sclerosis (ALS) cases result from impaired mutan

77 the natural history of familial amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations (ALS(SO

78 rontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) caused by this mutation.

79 Amyotrophic lateral sclerosis (ALS) has an immune component, but pre

80 ve population based-registers of amyotrophic lateral sclerosis (ALS) have operated in Europe for over

81 eroxide dismutase gene (sod1) to amyotrophic lateral sclerosis (ALS) in 1993, researchers have sought

82 In trying to model FUS-amyotrophic lateral sclerosis (ALS) in mouse it is clear that FUS is

83 Amyotrophic Lateral Sclerosis (ALS) is a complex neurodegenerative d

84 Amyotrophic lateral sclerosis (ALS) is a degenerative disorder that

85 Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron d

86 Amyotrophic lateral sclerosis (ALS) is a devastating adult-onset neu

87 Amyotrophic lateral sclerosis (ALS) is a devastating and incurable n

88 Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerati

89 Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron degenera

90 Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative dis

91 Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset neurolog

92 Amyotrophic lateral sclerosis (ALS) is a heterogeneous degenerative

93 Amyotrophic lateral sclerosis (ALS) is a heterogeneous disease with

94 Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative di

95 Amyotrophic lateral sclerosis (ALS) is a multifactorial lethal motor

96 Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease a

97 S rodents.SIGNIFICANCE STATEMENT Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease i

98 Amyotrophic lateral sclerosis (ALS) is a progressive and uniformly f

99 Amyotrophic lateral sclerosis (ALS) is a progressive and usually fat

100 Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron dy

101 Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerati

102 Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerati

103 Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerati

104 Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset ne

105 Amyotrophic lateral sclerosis (ALS) is a progressive, fatal disease

106 Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodeg

107 Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurode

108 ding of genetic aetiology of ALS.Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurode

109 Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurode

110 Amyotrophic lateral sclerosis (ALS) is an adult-onset degeneration o

111 Amyotrophic lateral sclerosis (ALS) is an idiopathic and fatal neuro

112 Amyotrophic lateral sclerosis (ALS) is caused by the progressive deg

113 Amyotrophic lateral sclerosis (ALS) is characterized by the degenera

114 Amyotrophic lateral sclerosis (ALS) is debilitating neurodegenerativ

115 curate differential diagnosis of amyotrophic lateral sclerosis (ALS) is lacking.

116 ht chain (NFL) as a biomarker in amyotrophic lateral sclerosis (ALS) is needed.

117 tor neuron (MN) vulnerability in amyotrophic lateral sclerosis (ALS) is not known.

118 The disease course of amyotrophic lateral sclerosis (ALS) is rapid and, because its pathop

119 Although amyotrophic lateral sclerosis (ALS) is relatively rare, the socioeco

120 Amyotrophic lateral sclerosis (ALS) is the most common adult degener

121 t defects in patient-derived MNs.Amyotrophic lateral sclerosis (ALS) leads to selective loss of motor

122 Amyotrophic lateral sclerosis (ALS) may be associated with low body

123 and functional rating scales in amyotrophic lateral sclerosis (ALS) may be due to symptom heterogene

124 (palmitoylated) in vitro and in amyotrophic lateral sclerosis (ALS) mouse models, and that S-acylati

125 recently recognized hallmark of Amyotrophic Lateral Sclerosis (ALS) pathogenesis.

126 onditions are overrepresented in amyotrophic lateral sclerosis (ALS) patient kindreds and psychiatric

127 ospinal fluid (CSF) and serum of amyotrophic lateral sclerosis (ALS) patients.

128 ethod was submitted to the DREAM Amyotrophic Lateral Sclerosis (ALS) Stratification Challenge.

129 Neurochemical markers of amyotrophic lateral sclerosis (ALS) that reflect underlying disease

130 (VAPB) gene have been linked to amyotrophic lateral sclerosis (ALS) type 8.

131 G) tube for patients living with amyotrophic lateral sclerosis (ALS) using data from a clinical regis

132 Modeling amyotrophic lateral sclerosis (ALS) with human induced pluripotent s

133 NALE: Biomarkers for survival in amyotrophic lateral sclerosis (ALS) would facilitate the development

134 ed to both familial and sporadic amyotrophic lateral sclerosis (ALS), a devastating, late-onset motor

135 We show using a mouse model of amyotrophic lateral sclerosis (ALS), a disease in which corticospina

136 uperoxide dismutase (SOD1) cause amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disea

137 the profilin 1 (PFN1) gene cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease cau

138 ma (FUS) cause familial forms of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease cha

139 identify reliable biomarkers of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative

140 -ethnic genetic data in sporadic amyotrophic lateral sclerosis (ALS), an adult-onset, rapidly progres

141 cord injury, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease.

142 an emphasis on fasciculations in amyotrophic lateral sclerosis (ALS), and in benign fasciculation syn

143 that is principally affected in amyotrophic lateral sclerosis (ALS), but it is widely known that ind

144 Apathy is a prominent symptom of amyotrophic lateral sclerosis (ALS), but measurement is confounded b

145 nd RNA-binding protein FUS cause amyotrophic lateral sclerosis (ALS), but the biophysical properties

146 he most common cause of familial amyotrophic lateral sclerosis (ALS), but the mechanisms underlying r

147 bar affect (PBA) is prevalent in amyotrophic lateral sclerosis (ALS), but there is limited informatio

148 neuromuscular disorders, such as amyotrophic lateral sclerosis (ALS), end life via respiratory failur

149 ly with the motor neuron disease amyotrophic lateral sclerosis (ALS), especially at the genetic level

150 ed in the brain of patients with amyotrophic lateral sclerosis (ALS), including carriers of the C9orf

151 Mutations in FUS cause amyotrophic lateral sclerosis (ALS), including some of the most aggr

152 ion in a patient with late-stage amyotrophic lateral sclerosis (ALS), involving a fully implanted bra

153 ), and its mutant form linked to amyotrophic lateral sclerosis (ALS), is also secreted by yeast upon

154 ture in microglia from models of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Al

155 , frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA),

156 lding and aggregation, including amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and A

157 1 (SOD1), which causes familial amyotrophic lateral sclerosis (ALS), self-propagation of aggregation

158 ia in relatives of patients with amyotrophic lateral sclerosis (ALS), suggesting an aetiological rela

159 a hallmark of advanced stages of amyotrophic lateral sclerosis (ALS), the role of microglial cells in

160 set Alzheimer disease (LOAD) and amyotrophic lateral sclerosis (ALS), two major neurodegenerative dis

161 genetic factors contributing to amyotrophic lateral sclerosis (ALS), we conducted whole-exome analys

162 e major pathological hallmark of amyotrophic lateral sclerosis (ALS), we generated mice in which muta

163 ral connectivity associated with amyotrophic lateral sclerosis (ALS), which extends beyond the motor

164 lammation is a major hallmark of amyotrophic lateral sclerosis (ALS), which is currently untreatable.

165 motor manifestations of sporadic amyotrophic lateral sclerosis (ALS), while rarely documented, reflec

166 chronic mitochondrial defects in Amytrophic Lateral Sclerosis (ALS)- and Alzheimer's disease (AD)-li

167 ent network analyses focusing on amyotrophic lateral sclerosis (ALS)-associated genes, such as optine

168 letion of TBK1, or expression of amyotrophic lateral sclerosis (ALS)-associated OPTN or TBK1 mutant b

169 of FUS inclusions is promoted by amyotrophic lateral sclerosis (ALS)-linked mutations, but the cellul

170 patients suffering from advanced amyotrophic lateral sclerosis (ALS)-two of them in permanent CLIS an

171 a negative prognostic factor in amyotrophic lateral sclerosis (ALS).

172 e loss of motor neurons (MNs) in amyotrophic lateral sclerosis (ALS).

173 rontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

174 emporal dementia (bvFTD) develop amyotrophic lateral sclerosis (ALS).

175 ed astrocyte and mouse models of amyotrophic lateral sclerosis (ALS).

176 in a form of distal myopathy and amyotrophic lateral sclerosis (ALS).

177 nal fluid (CSF) of patients with amyotrophic lateral sclerosis (ALS).

178 is compromised in patients with amyotrophic lateral sclerosis (ALS).

179 abolisms with the future risk of amyotrophic lateral sclerosis (ALS).

180 eads to progressive paralysis in amyotrophic lateral sclerosis (ALS).

181 can cause familial and sporadic amyotrophic lateral sclerosis (ALS).

182 er spinal cord injury and during amyotrophic lateral sclerosis (ALS).

183 y be associated with the risk of amyotrophic lateral sclerosis (ALS).

184 product of a causative gene for amyotrophic lateral sclerosis (ALS).

185 unction and neurodegeneration in amyotrophic lateral sclerosis (ALS).

186 ents TDP-25 and TDP-35 occurs in amyotrophic lateral sclerosis (ALS).

187 teostasis is a common feature of amyotrophic lateral sclerosis (ALS).

188 igators to develop new models of amyotrophic lateral sclerosis (ALS).

189 adult-onset degenerative disease amyotrophic lateral sclerosis (ALS).

190 olutions for pathologies such as amyotrophic lateral sclerosis (ALS).

191 pinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).

192 e-time-environment hypothesis in amyotrophic lateral sclerosis (ALS).

193 icated in the pathophysiology of amyotrophic lateral sclerosis (ALS).

194 pathogenesis and progression of amyotrophic lateral sclerosis (ALS).

195 kable variations in mortality in amyotrophic lateral sclerosis (ALS).

196 th similarities to some forms of amyotrophic lateral sclerosis (ALS).

197 a negative prognostic factor in amyotrophic lateral sclerosis (ALS).

198 mutant SOD1(G93A) mouse model of amyotrophic lateral sclerosis (ALS).

199 cated in human diseases, such as amyotrophic lateral sclerosis (ALS).

200 eurological disorders, including amyotrophic lateral sclerosis (ALS).

201 sociated with the development of amyotrophic lateral sclerosis (ALS).

202 ein (RBP) TAF15 is implicated in amyotrophic lateral sclerosis (ALS).

203 ed in both familial and sporadic amyotrophic lateral sclerosis (ALS).

204 rontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

205 odegenerative diseases including amyotrophic lateral sclerosis (ALS).

206 in the onset and progression of amyotrophic lateral sclerosis (ALS).

207 entified in patients affected by amyotrophic lateral sclerosis (ALS).

208 rly neuropathological feature of amyotrophic lateral sclerosis (ALS).

209 of the neurodegenerative disease amyotrophic lateral sclerosis (ALS).

210 D1(G93A) mice, a mouse model for amyotrophic lateral sclerosis (ALS).

211 the gene encoding SOD1 all cause amyotrophic lateral sclerosis (ALS).

212 f early physiological markers of amyotrophic lateral sclerosis (ALS).

213 a role in the pathophysiology of amyotrophic lateral sclerosis (ALS).

214 ne is a predictor of survival in amyotrophic lateral sclerosis (ALS).

215 toxicity in an inherited form of amyotrophic lateral sclerosis (ALS).

216 e causes of neurodegeneration in Amyotrophic lateral sclerosis (ALS).

217 associated with the prognosis of amyotrophic lateral sclerosis (ALS); however, there is still no cons

218 are known to be associated with Amyotrophic Lateral Sclerosis (ALS, motor neurone disease) (sporadic

219 results in the juvenile form of amyotrophic lateral sclerosis (ALS16), and a 20 amino-acid deletion

220 aplegia (HSP) and juvenile onset amyotrophic lateral sclerosis (ALS5).

221 in 2 is associated with familial amyotrophic lateral sclerosis, also contributes to defects in postsy

222 therapeutic targets shared with amyotrophic lateral sclerosis and Alzheimer disease.

223 ontotemporal lobar degeneration, amyotrophic lateral sclerosis and Alzheimer's disease (AD).

224 including Huntington's disease, amyotrophic lateral sclerosis and Alzheimer's disease.

225 urodegenerative diseases such as amyotrophic lateral sclerosis and Alzheimer's, Parkinson's, and Hunt

226 hallmark in approximately 95% of amyotrophic lateral sclerosis and approximately 60% of frontotempora

227 gene is the most common cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD

228 the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD

229 leotide repeat in C9orf72 causes amyotrophic lateral sclerosis and frontotemporal dementia (c9FTD/ALS

230 ns that cause C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia (C9RAN) an

231 nching from Drosophila models of amyotrophic lateral sclerosis and frontotemporal dementia, that TDP-

232 degenerative diseases, including amyotrophic lateral sclerosis and frontotemporal dementia.

233 ntron of the C9orf72 gene causes amyotrophic lateral sclerosis and frontotemporal dementia.

234 e most frequent genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia.

235 commonest known genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia.

236 degenerative diseases, including amyotrophic lateral sclerosis and frontotemporal lobar dementia.

237 ngton's and Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis.

238 otypes for C. elegans models for amyotrophic lateral sclerosis and Parkinson's disease, and show a pa

239 and alpha-synuclein, involved in amyotrophic lateral sclerosis and Parkinson's disease, respectively,

240 TDP-43 transgenic mouse model of amyotrophic lateral sclerosis and patients with sporadic amyotrophic

241 s in movement disorders, such as amyotrophic lateral sclerosis and rapid-onset dystonia parkinsonism,

242 ation of TDP-43 is a hallmark of amyotrophic lateral sclerosis and ubiquitin-positive frontotemporal

243 's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal lobar dementia are

244 ing stroke, Alzheimer's disease, amyotrophic lateral sclerosis, and Huntington's disease, share incre

245 trophy, spinal muscular atrophy, amyotrophic lateral sclerosis, and myotonic dystrophy type 1, were a

246 trophy, spinal muscular atrophy, amyotrophic lateral sclerosis, and myotonic dystrophy type 1.

247 results in experimental stroke, amyotrophic lateral sclerosis, and neurotrauma models.

248 (including autism, epilepsy, and amyotrophic lateral sclerosis) are underpinned by synaptic dysfuncti

249 e neuropathological overlap with amyotrophic lateral sclerosis, associated with some shared clinical

250 gated whether spread of a mutant amyotrophic lateral sclerosis-associated cytosolic superoxide dismut

251 OPTN, E50K and M98K, but not an amyotrophic lateral sclerosis-associated mutant, E478G, induced cell

252 and to motor unit dismantling in amyotrophic lateral sclerosis at late disease stage.

253 on's disease, and C9orf72-linked amyotrophic lateral sclerosis (C9-ALS).

254 reatments for C9ORF72-associated amyotrophic lateral sclerosis (c9ALS) approach clinical trials, the

255 1(G86R) mice, an animal model of amyotrophic lateral sclerosis, conduritol B epoxide preserved gangli

256 as causing a subset of familial amyotrophic lateral sclerosis (fALS) and more rarely causing distal

257 gene are causative for familial amyotrophic lateral sclerosis (fALS).

258 OD1 mutations linked to familial amyotrophic lateral sclerosis (fALS/SOD1).

259 nnervation, which degenerates in amyotrophic lateral sclerosis from the early disease stage.

260 system proteinopathies including amyotrophic lateral sclerosis, frontotemporal lobar degeneration, an

261 degenerative diseases, including amyotrophic lateral sclerosis, frontotemporal lobar dementia, and Al

262 sporadic frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) diseases, neither the normal

263 (n = 128), and of FTD cases with Amyotrophic Lateral Sclerosis (FTD-ALS; n = 7) to those of unaffecte

264 = 289), frontotemporal dementia/amyotrophic lateral sclerosis (FTD/ALS, n = 252), Creutzfeldt-Jakob

265 Main Outcomes and Measures: Amyotrophic lateral sclerosis function, measured using the ALS Funct

266 rics with changes on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R).

267 ic variation in a panel of known amyotrophic lateral sclerosis genes in 1126 patient samples and 613

268 o frontotemporal dementia and/or amyotrophic lateral sclerosis have highly variable ages at onset of

269 ical well-being in patients with amyotrophic lateral sclerosis-induced locked-in state and their next

270 ALS2 gene result in early-onset amyotrophic lateral sclerosis, infantile-onset ascending hereditary

271 Because amyotrophic lateral sclerosis is a fatal adult-onset neurodegenerati

272 Amyotrophic lateral sclerosis is a progressive adult-onset neurodege

273 Amyotrophic lateral sclerosis is a progressive neurodegenerative dis

274 Amyotrophic lateral sclerosis is characterised by the progressive lo

275 that the genetic architecture of amyotrophic lateral sclerosis is complex and that variation in the r

276 esignated HTB1M) of two familial amyotrophic lateral sclerosis-linked SOD1 mutants, SOD1(G93A) and SO

277 1 women) (group 2), 10 patients with primary lateral sclerosis (mean age +/- SD, 55.5 +/- 12 y; 3 men

278 ctional baseline analysis of the Amyotrophic Lateral Sclerosis Multicenter Cohort Study of Oxidative

279 cal diseases, including ataxias, amyotrophic lateral sclerosis, nucleotide expansion disorders (Fried

280 ers such as Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's

281 , including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, and the prototyp

282 dium pump in diseases, including amyotrophic lateral sclerosis, parkinsonism, epilepsy, and hemiplegi

283 (BMAA), a probable cause of the amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC

284 romising tools for understanding amyotrophic lateral sclerosis pathogenesis and testing new therapeut

285 es in the cerebrospinal fluid of amyotrophic lateral sclerosis patients in early disease stage.

286 Analysis of functionally linked amyotrophic lateral sclerosis proteins revealed recruitment of p62,

287 Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis, respectively.

288 rain trauma, multiple sclerosis, amyotrophic lateral sclerosis, sepsis, ischemic and reperfusion inju

289 ngs, including a murine model of amyotrophic lateral sclerosis (SOD1G93A), middle cerebral artery occ

290 ive autophagy in the broader FTD/amyotrophic lateral sclerosis spectrum of neurodegenerative disease.

291 ve motor neuron diseases such as amyotrophic lateral sclerosis, spinal muscular atrophy, and spinobul

292 reminiscent of those observed in amyotrophic lateral sclerosis, such as ubiquitin and p62 aggregates,

293 tary spastic paraplegia and juvenile primary lateral sclerosis, suggesting prominent upper motor neur

294 hile in Huntington's disease and amyotrophic lateral sclerosis they form in different cellular compar

295 ngs in transgenic mice and human amyotrophic lateral sclerosis tissues.

296 omotor apraxia type 2 (AOA2) and amyotrophic lateral sclerosis type 4 (ALS4).

297 zheimer's disease, and four with amyotrophic lateral sclerosis who lacked neurodegenerative disease-r

298 tations in FUS are causative for amyotrophic lateral sclerosis with a dominant mode of inheritance.

299 ), Parkinson's disease (PD), and amyotrophic lateral sclerosis with associated frontotemporal dementi

300 odies; Huntington's disease; and amyotrophic lateral sclerosis with dementia, as well as prion diseas